Zobrazeno 31 - 40
of 377
pro vyhledávání: '"Craig H. Moskowitz"'
Autor:
Steven M. Horwitz, Philip Caron, Pamela Drullinsky, Joachim Yahalom, Matthew J. Matasar, Connie Lee Batlevi, Anita Kumar, Esther Drill, A. Joseph, Audrey Hamilton, Ranjana H. Advani, Richard T. Hoppe, Heiko Schöder, Jonathan W. Friedberg, Joanna C. Yang, Elizabeth Budde, Paul A. Hamlin, Louis S. Constine, Maria Lia Palomba, Craig H. Moskowitz, Anas Younes, Shreya Vemuri, Andrew D. Zelenetz, Niloufer Khan, Clare Grieve, David J. Straus, Carla Casulo, Leana Laraque, Alison J. Moskowitz, Paul M. Barr, Ariela Noy, S.V. Dandapani
Publikováno v:
Journal of Clinical Oncology. 39:2257-2265
PURPOSE To improve curability and limit long-term adverse effects for newly diagnosed early-stage (ES), unfavorable-risk Hodgkin lymphoma. METHODS In this multicenter study with four sequential cohorts, patients received four cycles of brentuximab ve
Autor:
Miguel-Angel Perales, Molly Maloy, Sean M. Devlin, Erica Petrlik, Matthew J. Matasar, Craig H. Moskowitz, Esperanza B. Papadopoulos, Gunjan L. Shah, Josel D. Ruiz, Michael Scordo, Parastoo B. Dahi, Craig S. Sauter, Carlos Rondon-Clavo, Jasme Lee, Roni Tamari, Ann A. Jakubowski, Paul A. Hamlin, Sergio Giralt
Publikováno v:
Blood Adv
High-dose chemotherapy and autologous hematopoietic cell transplantation is an effective consolidation therapy in lymphoma; however, its use in elderly patients has been limited because of concerns for greater toxicity in this group. We investigated
Autor:
Juan Pablo Alderuccio, Thomas Habermann, Russ Kuker, Craig H. Moskowitz, Andrew D. Zelenetz, Izidore S. Lossos
Publikováno v:
American journal of hematology. 97(11)
Marginal zone lymphoma (MZL) is commonly underrepresented in clinical trials collectively studying mostly nodal indolent lymphomas.In this manuscript we propose new inclusion and response criteria defined by MZL subtype and disease location for those
Autor:
Laure, Michaud, Kurt, Bantilan, Audrey, Mauguen, Craig H, Moskowitz, Andrew D, Zelenetz, Heiko, Schöder
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
Early identification of patients with diffuse large B-cell lymphoma (DLBCL) who are likely to experience disease recurrence or refractory disease after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) would be useful
Autor:
Juan Pablo Alderuccio, Russ A. Kuker, David Lehmkuhl, Deukwoo Kwon, Andrea Cordoba, Weizhao Zhao, Izidore S. Lossos, Craig H. Moskowitz, Fei Yang
Publikováno v:
Blood. 140:4972-4973
Autor:
Craig H. Moskowitz, Alvaro J. Alencar
Publikováno v:
Journal of Clinical Oncology. 39:467-475
Autor:
Esther Drill, Steven M. Horwitz, Carol S. Portlock, Sridevi Rajeeve, Matthew J. Matasar, Anas Younes, Ariela Noy, John F. Gerecitano, Erel Joffe, Yan Leyfman, Craig H. Moskowitz, David J. Straus, Connie Lee Batlevi, Anita Kumar, M. Lia Palomba, Andrew D. Zelenetz, Alison J. Moskowitz, Paul A. Hamlin
Publikováno v:
Blood Adv
Although patients with bronchus-associated lymphoid tissue (BALT) lymphoma show an indolent clinical course, appropriate disease management at diagnosis is not well defined. This study aimed to compare 3 treatment strategies for patients with BALT ly
Autor:
Francesco Maura, Bachisio Ziccheddu, Jenny Z. Xiang, Bhavneet Bhinder, Federico Abascal, Kylee H. Maclachlan, Kenneth Wha Eng, Manik Uppal, Feng He, Wei Zhang, Qi Gao, Venkata Yellapantula, Sunita Park, Matthew Oberley, Elizabeth Ruckdeschel, Megan S. Lim, Gerald Wertheim, Matthew Barth, Terzah M. Horton, Christopher Forlenza, Yanming Zhang, Ola Landgren, Craig H Moskowitz, Ethel Cesarman, Marcin Imielinski, Olivier Elemento, Mikhail Roshal, Lisa Giulino-Roth
The rarity of malignant Hodgkin and Reed Sternberg (HRS) cells within a classic Hodgkin lymphoma (cHL) biopsy limits the ability to study the genomics of cHL. To circumvent this, our group has previously optimized fluorescence-activated cell sorting
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1eeb685f67c1465fc218d0c7a00cb349
https://doi.org/10.1101/2021.11.05.467496
https://doi.org/10.1101/2021.11.05.467496
Publikováno v:
Clinical lymphoma, myelomaleukemia. 22(6)
Introduction The treatment landscape for diffuse large B-cell lymphoma (DLBCL) has recently changed. We examined characteristics and clinical outcomes of DLBCL patients who initiated a third (3L) and fourth (4L) line of therapy during a contemporary
Autor:
Parastoo B. Dahi, Alexander Geyer, Sheila Kenny, Jessica Flynn, Sean M. Devlin, Josel D. Ruiz, Oscar B. Lahoud, Matthew J. Matasar, Craig H. Moskowitz, Miguel-Angel Perales, Gunjan Shah, Craig S. Sauter, Sergio A Giralt, Ann A. Jakubowski
Publikováno v:
Transplantation and Cellular Therapy. 28:S390-S391